摘要
目的:评价福建省医疗保险管理中心铁路分中心(简称"我中心")二级以上定点医院胸腺五肽(TP-5)注射剂的应用情况。方法:调取我中心24家定点医院2010年1-6月应用TP-5注射剂的339份住院患者病历,根据医疗待遇、出院诊断分别统计费用、住院时间、现金支付比例等数据以及联合应用免疫增强剂的情况。结果:住院时间、现金支付比例、患者年龄等因素均能影响TP-5注射剂的临床应用;29.77%的患者无用药指征;52.51%的病例联用1种及以上免疫增强剂。结论:我中心定点医院TP-5注射剂临床应用存在不合理现象;联合应用免疫增强剂可能存在过度医疗行为;各级监管部门应制定有针对性的措施以遏制医疗费用过快增长。
OBJECTIVE: To evaluate the application of Thymopentin (TP-5) injections in grade II - III general hospitals of Railway Branch of Fujian Province Medical Insurance Management Center (called "our center" in short). METHODS: Medical records of 339 inpatients who used TP-5 injection from Jan. 2010 to Jun. 2010 were collected from 24 hospitals of our center. According to insured medical treatment and discharge diagnosis, the cost, hospitalization days, cash-payment ratio, the combined use of immunopotentiator were analyzed statistically. RESULTS: The application of TP-5 injection was affected by some factors such as hospitalization day, cash-payment ratio and age of patients, etc. About 29.77% of patients were without the use of the drug indica- tions; about 52.51% of patients used more than one kind of immunopotentiator. CONCLUSION: The uses of TP-5 injections are ir- rational in hospitals of our center. Combined use of immunopotentiator is excessive. Medical supervision department ought to make some focal methods to restrain the upward of medical expense.
出处
《中国药房》
CAS
CSCD
2012年第6期517-519,共3页
China Pharmacy
关键词
胸腺五肽注射剂
免疫增强剂
医疗保险
医疗监管
Thymopentin injection
lmmunopotentiator
Medical insurance
Medical supervision